ArticleNPJ science of food2026
Advances in synbiotics and synbiotic functional foods in type 2 diabetes mellitus treatment.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing incidence of type 2 diabetes mellitus (T2DM) globally necessitates alternative therapeutic strategies. Evidence suggests that intestinal microbiota significantly influences T2DM development, leading to the proposal of probiotics as potential treatments. However, challenges such as strain selectivity and low survival rates limit probiotics' effectiveness. Combining probiotics with prebiotics, known as synbiotics, offers a promising approach for managing T2DM. The development of synbiotic-based functional foods also provides effective interventions for T2DM. This article synthesizes the recent advancements of synbiotics and synbiotic functional foods in managing T2DM, covering 40 studies, of which 29 studies employed synbiotics, and 11 studies employed synbiotic functional foods. In the 21 human studies, 17 focused on T2DM treatment and another 4 on the prevention of prediabetes from developing to T2DM. As for probiotics, 20 studies used single-strain probiotics, while others employed multiple strains, with 5 focusing on the synbiotics combined with hypoglycemic substances. Overall, synbiotics and synbiotic functional foods offer therapeutic benefits by reducing inflammation and oxidative stress, regulating gut microbiota, enhancing short-chain fatty acids, and improving intestinal barrier function. Further research is crucial to determine optimal formulations, dosages, and long-term safety, along with developing new synbiotic functional foods for effective diabetes interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.